www.hiv-druginteractions.org LIVERPOOL

Interaction Report

Report ID: 11 May 2025 Date Produced:

Antiretroviral Treatment	Co-medications
Dolutegravir (DTG)	Magnesium supplements

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org .

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Dolutegravir (DTG) + Magnesium supplements

Coadministration has not been studied. Magnesium is eliminated in kidney, mainly by glomerular filtration. Dolutegravir binds to divalent cations, such as magnesium, and forms a complex at the level of the gastro-intestinal tract which results in less dolutegravir being absorbed. Dolutegravir should be administered 2 hours before or 6 hours after taking medications containing magnesium.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

s report is provided for information or inicians must exercise their own judg the University of Liverpool harmless currency of info an appropriately qualified health professional. Info ining drugs, which depend on factors beyond phan We aim to ensure that inform effects of interacting medications, and is b ersity of Liverpool shall not be held respons ever, the University of Liverpool and its sen expressly exclude liability for a t data in the public domain. No clinical advice is given or imp ication or use of any information it gives and the user shall h shall not be responsible or in any way liable for the continued is to the fullet acted regretized by law. based on relevant out... nsible for the application or use of any mu-ervants or agents shall not be responsible of incomracies to the fullest extent p elates only to known or suspecte ons between two drugs. The Un fits of co